NAGE (Niagen) Gross Profit Margin

Chromadex Corp (NAGE) innovations in cellular longevity and DNA repair are driving the upward trend in gross profit margins. This growth is supported by patent protection of production, strict FDA oversight, and the retention of a staff of leading biochemists. The current metric stands at 63.90, confirming high commercial efficiency and the strengthening of the company's market position.
Financial and market metric breakdowns for Chromadex Corp (NAGE)

To assess the long-term sustainability of Chromadex Corp (NAGE), it is critical to analyze the portion of revenue remaining after paying direct production costs, as reflected in the gross margin. This metric measures the efficiency of supplement cost management, confirming the company's ability to generate profit through exclusive retail distribution without capital-intensive M&A transactions.